Treatment Information

Back

Lung Cancer treatment details. Chemotherapy.

University Medical Center Groningen, Groningen, Netherlands.

Survival: monthsCountry:Netherlands
Toxiciy Grade:5City/State/Province:Groningen
Treatments:ChemotherapyHospital:University Medical Center Groningen
Drugs:Journal:Link
Date:Nov 2011

Description:

Patients:
This phase 3 study involved advanced non-small cell lung cancer patients, who had not been previously treated with chemotherapy and were divided into two separate treatment groups. Group A consisted of 281 patients with a median age of 62 years; 65% were male. Group B had 280 patients, 61% male, and a median patient age of 61 years.

Treatment:
Patients in group A were treated with the chemotherapy agents docetaxel and carboplatin, as well as the biologic therapy agent celecoxib (also known as Celebrex), which is an anti-inflammatory medicine.

Patients in group B were treated with docetaxel and carboplatin only.

Toxicities:
Treatment-related deaths due to unspecified causes were reported in group A. Grade 3-4 neutropenia, fatigue, and leukopenia were also reported.

Treatment-related deaths due to unspecified causes were reported in group B. Grade 3-4 neutropenia, fatigue, and leukopenia were also reported.

Results:
The median overall survival rate for both group A and group B was 8.2 months.

Support:
This study was supported by the pharmaceutical company Pfizer.

Correspondence: Dr. Harry J.M. Groen; email: [email protected]



Back